TETRAPHASE PHARMACEUTICALS INC Operating Expenses
TETRAPHASE PHARMACEUTICALS INC reported Operating Expenses of $14.02 million for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2020-05-07
- TETRAPHASE PHARMACEUTICALS INC operating expenses for the quarter ending 2020-03-31 was $14.02M, a 30.99% decline year-over-year.
- TETRAPHASE PHARMACEUTICALS INC operating expenses for the quarter ending 2019-12-31 was $13.23M, a 48.46% decline year-over-year.
- TETRAPHASE PHARMACEUTICALS INC operating expenses for the quarter ending 2019-09-30 was $17.68M, a 16.40% decline year-over-year.
- TETRAPHASE PHARMACEUTICALS INC operating expenses for the quarter ending 2019-06-30 was $23.68M, a 9.98% increase year-over-year.
- TETRAPHASE PHARMACEUTICALS INC operating expenses for fiscal 2019 was $74.91M, a 18.74% decline from fiscal 2018.
- TETRAPHASE PHARMACEUTICALS INC operating expenses for fiscal 2018 was $92.19M, a 26.48% decline from fiscal 2017.
- TETRAPHASE PHARMACEUTICALS INC operating expenses for fiscal 2017 was $125.38M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2020-03-31 | $14.02M 10-Q · filed 2020-05-07 | $27.25M derived: sum of 2 quarters · filed 2020-05-07 | $44.93M derived: sum of 3 quarters · filed 2020-05-07 | $68.61M derived: sum of 4 quarters · filed 2020-05-07 |
| 2019-12-31 | $13.23M 10-K · filed 2020-03-12 | $30.91M derived: sum of 2 quarters · filed 2020-03-12 | $54.59M derived: sum of 3 quarters · filed 2020-03-12 | $74.91M 10-K · filed 2020-03-12 |
| 2019-09-30 | $17.68M 10-K · filed 2020-03-12 | $41.36M derived: sum of 2 quarters · filed 2020-03-12 | $61.68M 10-Q · filed 2019-11-12 | $87.35M derived: sum of 4 quarters · filed 2020-05-07 |
| 2019-06-30 | $23.68M 10-K · filed 2020-03-12 | $44.00M 10-Q · filed 2019-08-08 | $69.67M derived: sum of 3 quarters · filed 2020-05-07 | $90.82M derived: sum of 4 quarters · filed 2020-05-07 |
| 2019-03-31 | $20.31M 10-Q · filed 2020-05-07 | $45.98M derived: sum of 2 quarters · filed 2020-05-07 | $67.13M derived: sum of 3 quarters · filed 2020-05-07 | $88.67M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $25.67M 10-K · filed 2020-03-12 | $46.82M derived: sum of 2 quarters · filed 2020-03-12 | $68.35M derived: sum of 3 quarters · filed 2020-03-12 | $92.19M 10-K · filed 2020-03-12 |
| 2018-09-30 | $21.15M 10-K · filed 2020-03-12 | $42.68M derived: sum of 2 quarters · filed 2020-03-12 | $66.51M 10-Q · filed 2019-11-12 | $92.86M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | $21.54M 10-K · filed 2020-03-12 | $45.37M 10-Q · filed 2019-08-08 | $71.71M derived: sum of 3 quarters · filed 2020-03-12 | $106.09M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | $23.83M 10-K · filed 2020-03-12 | $50.18M derived: sum of 2 quarters · filed 2020-03-12 | $84.56M derived: sum of 3 quarters · filed 2020-03-12 | $118.13M derived: sum of 4 quarters · filed 2020-03-12 |
| 2017-12-31 | $26.35M 10-K · filed 2019-03-15 | $60.72M derived: sum of 2 quarters · filed 2019-03-15 | $94.30M derived: sum of 3 quarters · filed 2019-03-15 | $125.38M 10-K · filed 2019-03-15 |
| 2017-09-30 | $34.38M 10-K · filed 2019-03-15 | $67.95M derived: sum of 2 quarters · filed 2019-03-15 | $99.03M derived: sum of 3 quarters · filed 2019-03-15 | |
| 2017-06-30 | $33.58M 10-K · filed 2019-03-15 | $64.66M derived: sum of 2 quarters · filed 2019-03-15 | ||
| 2017-03-31 | $31.08M 10-K · filed 2019-03-15 |